MetLife Investment Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $209K | Buy |
+32,682
| New | +$209K | ﹤0.01% | 2165 |
|
2024
Q3 | – | Hold |
0
| – | – | – | 2868 |
|
2024
Q2 | – | Hold |
0
| – | – | – | 2894 |
|
2024
Q1 | – | Sell |
-27,395
| Closed | -$65.7K | – | 2794 |
|
2023
Q4 | $65.7K | Hold |
27,395
| – | – | ﹤0.01% | 2749 |
|
2023
Q3 | $93.1K | Hold |
27,395
| – | – | ﹤0.01% | 2616 |
|
2023
Q2 | $201K | Hold |
27,395
| – | – | ﹤0.01% | 2274 |
|
2023
Q1 | $284K | Hold |
27,395
| – | – | ﹤0.01% | 2001 |
|
2022
Q4 | $324K | Hold |
27,395
| – | – | ﹤0.01% | 1919 |
|
2022
Q3 | $575K | Hold |
27,395
| – | – | ﹤0.01% | 1535 |
|
2022
Q2 | $850K | Hold |
27,395
| – | – | 0.01% | 1295 |
|
2022
Q1 | $1.12M | Buy |
27,395
+9,797
| +56% | +$402K | 0.01% | 1258 |
|
2021
Q4 | $765K | Sell |
17,598
-22,960
| -57% | -$998K | 0.01% | 1254 |
|
2021
Q3 | $2.03M | Buy |
40,558
+201
| +0.5% | +$10.1K | 0.02% | 851 |
|
2021
Q2 | $2.54M | Sell |
40,357
-643
| -2% | -$40.5K | 0.02% | 766 |
|
2021
Q1 | $3.81M | Sell |
41,000
-2,365
| -5% | -$220K | 0.03% | 535 |
|
2020
Q4 | $3.89M | Sell |
43,365
-1,105
| -2% | -$99K | 0.04% | 480 |
|
2020
Q3 | $4.6M | Buy |
44,470
+24,459
| +122% | +$2.53M | 0.05% | 341 |
|
2020
Q2 | $1.58M | Hold |
20,011
| – | – | 0.02% | 827 |
|
2020
Q1 | $1.16M | Hold |
20,011
| – | – | 0.02% | 838 |
|
2019
Q4 | $1.08M | Hold |
20,011
| – | – | 0.01% | 1063 |
|
2019
Q3 | $1.05M | Hold |
20,011
| – | – | 0.01% | 1044 |
|
2019
Q2 | $967K | Hold |
20,011
| – | – | 0.01% | 1118 |
|
2019
Q1 | $1.01M | Hold |
20,011
| – | – | 0.01% | 1079 |
|
2018
Q4 | $1.19M | Buy |
20,011
+1,170
| +6% | +$69.4K | 0.01% | 957 |
|
2018
Q3 | $1.24M | Sell |
18,841
-1,671
| -8% | -$110K | 0.01% | 1035 |
|
2018
Q2 | $1.04M | Buy |
20,512
+4,795
| +31% | +$242K | 0.01% | 1005 |
|
2018
Q1 | $828K | Hold |
15,717
| – | – | 0.01% | 1093 |
|
2017
Q4 | $730K | Buy |
+15,717
| New | +$730K | 0.01% | 1182 |
|